Accessed March 31, 2026
Research has identified these alarming vision-related risks associated with GLP-1 medications: Sudden irreversible vision loss: NAION strikes without warning, often discovered upon waking, causing blurry or dim vision that progresses to immediate and permanent partial or complete blindness in the affected eye with no possibility of restoration Elevated risk across multiple studies: Beyond the Harvard findings showing 4-7 fold increased risk, a University of Southern Denmark study examining over 424,000 patients found weekly semaglutide users faced 2.19 times higher NAION risk European regulatory recognition: In June 2025, the European Medicines Agency officially recognized NAION as a possible side effect of semaglutide medications, marking formal acknowledgment by international regulators Complete absence of treatment options: Medical science currently offers no cure, no effective treatment, and no way to reverse NAION-related vision damage, leaving patients with permanent disability The permanent and irreversible nature of NAION-related optic nerve damage distinguishes these injuries from other complications that may resolve after discontinuing medication
Vikings VK2735 is a dual GLP-1/GIP agonist, which generally provides higher efficacy than the single-agonist GLP-1 drugs currently in AstraZenecas early-stage pipeline
cardio
Using the retatrutide dosage calculator can help researchers determine exact reconstitution volumes for their target concentrations
Tetrahydrobiopterin Biosynthesis as an Off-Target of Sulfa Drugs. Science (New York, N.Y.) , vol
